Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
48
AXGN Quote, Financials, Valuation and Earnings
Last price:
$15.62
Seasonality move
:
6.77%
Day range:
$14.54 - $15.89
52-week range:
$5.55 - $15.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.76x
P/B ratio:
6.92x
Volume:
1.1M
Avg. volume:
297.4K
1-year change:
124.96%
Market cap:
$688.1M
Revenue:
$159M
EPS (TTM):
-$0.32
Analysts' Opinion
-
Consensus RatingAxogen has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Axogen has an estimated upside of 15.13% from its current price of $15.64.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $15.64.
Fair Value
-
According to the consensus of 0 analysts, Axogen has 15.13% upside to fair value with a price target of -- per share.
AXGN vs. S&P 500
-
Over the past 5 trading days, Axogen has overperformed the S&P 500 by 12.66% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Axogen does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Axogen has grown year-over-year revenues for 10 quarters straight. In the most recent quarter Axogen reported revenues of $48.6M.
Earnings Growth
-
Axogen earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Axogen reported earnings per share of -$0.04.
Enterprise value:
710.8M
EV / Invested capital:
4.85x
Price / LTM sales:
3.76x
EV / EBIT:
--
EV / Revenue:
3.93x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-71.81x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
414.47x
Gross Profit (TTM):
$142.4M
Return On Assets:
-7.46%
Net Income Margin (TTM):
-7.91%
Return On Equity:
-14.85%
Return On Invested Capital:
-9.99%
Operating Margin:
-0.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $134M | $152.3M | $180.9M | $41.3M | $48.6M | |
| Gross Profit | $110.5M | $119.9M | $142.4M | $31.7M | $36.4M | |
| Operating Income | -$29.5M | -$23.9M | -$8.5M | -$4M | -$316K | |
| EBITDA | -$23.4M | -$17.4M | $1.7M | -$1.9M | $2M | |
| Diluted EPS | -$0.67 | -$0.56 | -$0.32 | -$0.10 | -$0.04 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $140M | $135M | $102.5M | $87.4M | $86.3M | |
| Total Assets | $193.9M | $210M | $195.5M | $194.6M | $192M | |
| Current Liabilities | $18.8M | $23.4M | $23.5M | $26.6M | $23M | |
| Total Liabilities | $72.2M | $94.7M | $94.1M | $96.8M | $92.6M | |
| Total Equity | $121.7M | $115.3M | $101.4M | $97.8M | $99.4M | |
| Total Debt | $31.8M | $46.2M | $45.5M | $46.4M | $47.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18.9M | -$4.1M | -$4.4M | $1.6M | $3.9M | |
| Cash From Investing | -$15.6M | $18.3M | -$9.8M | $6M | -$5M | |
| Cash From Financing | $2M | $2.3M | $1.7M | $5K | $572K | |
| Free Cash Flow | -$40.7M | -$24.1M | -$9.9M | -$2.3M | $2.8M | |
AXGN
Sector
Market Cap
$688.1M
$44.6M
Price % of 52-Week High
98.33%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
124.96%
-29.09%
Beta (5-Year)
1.063
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$14.68
200-day SMA
Buy
Level
$10.29
Bollinger Bands (100)
Buy
Level
11.57 - 14.85
Chaikin Money Flow
Buy
Level
18.6M
20-day SMA
Buy
Level
$14.44
Relative Strength Index (RSI14)
Buy
Level
64.40
ADX Line
Buy
Level
13.39
Williams %R
Sell
Level
-12.5
50-day SMA
Buy
Level
$13.93
MACD (12, 26)
Buy
Level
0.34
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
45.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.5885)
Sell
CA Score
(Annual)
Level (-0.5743)
Buy
Beneish M-Score
(Annual)
Level (-2.6509)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (1.7551)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Stock Forecast FAQ
In the current month, AXGN has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AXGN average analyst price target in the past 3 months is --.
-
Where Will Axogen Stock Be In 1 Year?
According to analysts, the consensus estimate is that Axogen share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Axogen?
Analysts are divided on their view about Axogen share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Axogen is a Sell and believe this share price will drop from its current level to --.
-
What Is Axogen's Price Target?
The price target for Axogen over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AXGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Axogen is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AXGN?
You can purchase shares of Axogen via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Axogen shares.
-
What Is The Axogen Share Price Today?
Axogen was last trading at $15.62 per share. This represents the most recent stock quote for Axogen. Yesterday, Axogen closed at $15.64 per share.
-
How To Buy Axogen Stock Online?
In order to purchase Axogen stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
